Government Launches £38m Biomanufacturing Fund
Grants are available to support businesses investing in vaccines manufacturing projects in the UK.
The Biomanufacturing Fund will provide capital grants to incentivise investment in the manufacture of vaccines and biotherapeutics, to improve the UK’s health resilience for future pandemics.
The scheme particularly welcomes applications for the manufacture of:
- Drug substance (for example active pharmaceutical ingredient (API).
- Finished drug product (for example fill/finish).
- Component materials (such as starting materials, delivery systems, adjuvants).
The Fund will provide up to £38 million in capital grants. The minimum total project cost is £12 million. There is no upper limit on total project cost or the level of grant that may be requested. However, in allocating funding the Government is looking to support a portfolio of investments rather than a single, very large investment.
Applications are accepted from UK manufacturers (this could be manufacturing products for clinical trials or for commercial sale). Manufacturing relates to the manufacture of human medicines.
Projects can be for the upgrade, expansion or establishment of new manufacturing facilities, and are likely to include both building infrastructure (eg air handling, the building), buying land and manufacturing equipment.
The Phase 1 Wave 1 deadline for Expressions of Interest is 30 June 2023 (12:00 BST).
(This report was the subject of a GRANTfinder Newsflash.)
